Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

INCY 11.18.2024

Full Press ReleaseSEC FilingsOur INCY Tweets

About Gravity Analytica

Recent News

  • 02.10.2025 - Q4 2024 Incyte Corporation Earnings Conference Call
  • 01.21.2025 - Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
  • 01.15.2025 - Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.21.2025 - 144 Report of proposed sale of securities
PDF Version

WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 18, 2024--Incyte(Nasdaq:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings.

These data have been shared with theU.S. Food and Drug Administration(FDA) andIncytewill work closely with the FDA to determine next steps.

Enrollment in the other INCB000262 proof-of-concept studies is complete and data from all clinical studies will help inform its future development and guide the potential development of back-up molecules.

In addition, data from the Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus (CP) does not support further development.

AboutIncyte

A global biopharmaceutical company on a mission toSolve On.,Incytefollows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics,Incytehas established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered inWilmington, Delaware,Incytehas operations inNorth America,EuropeandAsia.

For additional information onIncyte, please visitIncyte.comor follow us on social media:LinkedIn,X,Instagram,Facebook,YouTube.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including any discussion of the ongoing Phase 2 study of MRGPRX2 (INCB000262), Incyte’s decision to pause enrollment in that study, Incyte’s intent to work with FDA to determine next steps, and future development of INCB000262 and other back-up molecules.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: further research and development and the possibility that results of clinical trials will be negative and/or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by FDA and other regulatory agencies; the efficacy or safety of Incyte’s products; the acceptance of Incyte’s products in the marketplace; market competition; unexpected variations in the supply of and/or demand for Incyte’s products; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for Incyte’s products; sales, marketing, manufacturing and distribution requirements, including Incyte’s ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional products that become approved; greater than expected expenses, including expenses relating to litigation or strategic activities; variations in foreign currency exchange rates; and other risks detailed in Incyte’s reports filed with theSecurities and Exchange Commission, including its quarterly report on form 10-Q for the quarter endedSeptember 30, 2024.Incytedisclaims any intent or obligation to update these forward-looking statements.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241118391127/en/

Mediamedia@incyte.com

Investorsir@incyte.com

Source:Incyte

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com